Drug Patent Expiration: The Hidden Work Before a Generic Launch
FDA listed 91 first generic drug approvals for 2025 [2]. Each one passed through a chain of checks that a
Drug Patent Expiration: The Hidden Work Before a Generic Launch Read Post »
Global Patent Expiration Dates: One Drug, Many Clocks
The European Medicines Agency authorized Eliquis (apixaban) on 18 May 2011 [10]. The compound patent behind it, EP 1 427
Global Patent Expiration Dates: One Drug, Many Clocks Read Post »
Patent Expiration Isn’t Generic Entry: How to Find the Date That Counts
The main US combination patent for Entresto expired on July 15, 2025, with its pediatric exclusivity. [1] Novartis’s own 2023
Patent Expiration Isn’t Generic Entry: How to Find the Date That Counts Read Post »
The Philippines Pharma Opportunity Map: What Patent Expirations Can and Cannot Tell You
In 2024, the Intellectual Property Office of the Philippines (IPOPHL) granted 2,063 patents. Non-residents received 1,958 of them. That is
The Philippines Pharma Opportunity Map: What Patent Expirations Can and Cannot Tell You Read Post »
How to Screen 10,000 Expiring Drug Patents Without Creating a 10,000-Row Research Project
FDA listed 91 first generic drug approvals for 2025. [1] Evaluate reports that more than $300 billion in prescription drug
Patent Expiration Is a Trigger. What You Really Need Is the Opportunity Behind It.
Merck says U.S. Patent No. 7,326,708 covers the sitagliptin salt in Januvia and expires on November 24, 2026 [1]. Settlements
Patent Expiration Is a Trigger. What You Really Need Is the Opportunity Behind It. Read Post »
Loss of Exclusivity vs. Patent Expiration: Track the Date That Moves Revenue
Humira had U.S. net revenues of $21.237 billion in 2022. [1] It made up about 37% of AbbVie’s total net
Loss of Exclusivity vs. Patent Expiration: Track the Date That Moves Revenue Read Post »
More Patents, Less Signal: Why a Bigger Drug Patent Database Can Give You Worse Intelligence
I-MAK counts 257 U.S. patent applications and 130 granted U.S. patents on Humira (adalimumab) [1]. In its 2016 BPCIA suit
Delisted Drug Patents: Six Ways a Patent Leaves the Orange Book, and What Each Exit Changes
On December 10, 2025, Teva asked FDA to remove more than 200 patent listings from the Orange Book. [1] The
